Innovent Biologics sees strong H1 2025 revenue and profit growth

Innovent Biologics, Inc. announced total revenue of RMB5,953.1 million for the first half of 2025, a substantial 50.6% year-over-year increase from RMB3,952.3 million in H1 2024. This growth was fueled by strong oncology product sales, an expanded general biomedicine portfolio, and increased license fee income, which reached RMB665.6 million, up from RMB115.9 million in the prior-year period. IFRS net profit significantly improved to RMB834.3 million, a turnaround from a RMB392.6 million loss in H1 2024. Non-IFRS profit also rose to RMB1,213.2 million, compared to a Non-IFRS loss of RMB160.2 million in the previous year.

Gross profit increased by RMB1,844.9 million to RMB5,119.6 million, with the gross profit margin expanding by 3.1 percentage points to 86.0%. R&D expenses were RMB1,008.8 million, down from RMB1,399.4 million in H1 2024, reflecting capital efficiency. Selling and marketing expenses totaled RMB2,375.1 million, accounting for 39.9% of total revenue. As of June 30, 2025, the company had RMB11,002.9 million in cash reserves and available unutilized long-term bank loan facilities of approximately RMB4,011.5 million.

The company's product portfolio expanded to 16 marketed products, with five new launches including DOVBLERON, limertinib, Jaypirca, SYCUME, and mazdutide. Innovent also advanced several pipeline assets into registrational or Phase 3 clinical development, with two new drug applications under regulatory review, four assets in Phase 3 or pivotal clinical trials, and 15 molecules in early clinical stages.